Karolinska Institutet seeks partnership with Kael Gemvax over GV1001
Published: 2013-08-23 06:59:00
Updated: 2013-08-23 06:59:00
Sweden based Karolinska Institutet, one of Europe's largest and most prestigious medical universities, sent out a letter of intent (LOI) to Kael Gemvax to jointly conduct Phase II clinical trial of GV 1001, Kael Gemvax officials said Wednesday.
GV1001 is a universal anti-telomerase therapeutic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
